Skip to search formSkip to main contentSkip to account menu

Sch 21420

Known as: Sch-21420 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1990
Highly Cited
1990
Following the use of amikacin as the principal aminoglycoside at a Denver hospital, amikacin resistance appeared first in… 
1980
1980
Disk susceptibility tests with two structurally related aminoglycosides (amikacin and Sch 21420) were evaluated. Tests with 10… 
1980
1980
Sch 21420 is a new aminoglycoside synthesized from gentamicin B. Susceptibility tests with Sch 21420, amikacin, gentamicin… 
1979
1979
The nephrotoxic potentials of the new aminoglycoside SCH 21420 and amikacin were compared in a rat model. Groups of rats received… 
1978
1978
In vitro tests were performed with Sch 21420 and Sch 22591 to determine (i) their activity in comparison to six other… 
1978
1978
Sch 21420, the 1-N-HAPA derivative of gentamicin B, has been compared to gentamicin, tobramycin and amikacin in a variety of in… 
1978
1978
The minimal inhibitory concentration of Sch-21420 closely paralleled amikacin for 125 strains of aerobic gram-negative bacilli… 
1978
1978
The activities of Sch 21420 and amikacin were compared in vitro against 448 clinical bacterial isolates and against 82 gentamicin… 
1978
1978
With the increasing prevalence of Gramnegative bacilli resistant to existing aminoglycosides, new semisynthetic aminoglycosides… 
1978
1978
Schering Compound Sch 21420 is an aminoglycoside with antibacterial activity similar to amikacin but with a potential for renal…